he FLOURISH study (NCT04391283) was a prospective, multicenter, non-interventional study evaluating first-line osimertinib in 481 treatment-naïve Chinese patients with EGFR-mutated advanced NSCLC across 22 sites. (IMAGE)
Caption
The FLOURISH study (NCT04391283) was a prospective, multicenter, non-interventional study evaluating first-line osimertinib in 481 treatment-naïve Chinese patients with EGFR-mutated advanced NSCLC across 22 sites. First, the study background and rationale are presented, highlighting the limited real-world evidence of first-line osimertinib in Chinese populations. Subsequently, the study design, patient flow, endpoint definitions, and subgroup analysis framework are described, including analyses by EGFR mutation type, CNS metastasis status, FLAURA eligibility, and co-mutation status. Next, key efficacy outcomes are summarized for the FAS population. Consistent clinical benefit was also observed in FLAURA-ineligible patients, whereas patients bearing co-mutations exhibited diminished clinical benefit. Finally, the key findings and clinical implications are highlighted. CNS, central nervous system; DCR, disease control rate; EGFR, epidermal growth factor receptor; FAS, full analysis set; NGS, next-generation sequencing; NSCLC, non-small cell lung cancer; ORR, objective response rate; OS, overall survival; rwPFS, real-world progression-free survival; TTD, time to treatment discontinuation.
Credit
Cancer Biology & Medicine
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted.
License
CC BY-NC